CTY.US City Therapeutics, Inc. Common Stock
- Market cap
- USD 911M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is CTY.US undervalued?
Graham numberThe Graham number of City Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
City Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for City Therapeutics, Inc. Common Stock yet.
City Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger mol…
Full company profileCity Therapeutics, Inc. Common Stock financial statements
City Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 8.85B | 8.75B | 8.84B | 8.96B | 8.91B | 8.55B | 8.49B | 8.16B | 2.78M | 13.6M |
| Gross Profit | 5.98B | 5.96B | 5.96B | 6.09B | 5.98B | 5.67B | 5.73B | 5.72B | - | - |
| Operating Income | 1.91B | 2.08B | 2.11B | 2.26B | 2.32B | 2.31B | 2.66B | 2.88B | -29.1M | -59.9M |
| EBITDA | 4.06B | 4.09B | 4.04B | 4.05B | 3.92B | 3.84B | 4.04B | 3.83B | -27.0M | -55.1M |
| Net Income | 849M | 964M | 970M | 1.07B | 1.09B | 1.66B | 1.67B | 1.83B | -27.8M | -58.5M |
| EPS | - | - | - | - | - | - | - | - | -0.58 | -1.21 |
| Balance Sheet | ||||||||||
| Total Assets | 16.7B | 16.0B | 22.5B | 21.5B | 21.1B | 20.9B | 20.6B | 21.0B | 145M | 150M |
| Total Liabilities | 14.0B | 13.6B | 13.3B | 12.6B | 12.5B | 11.5B | 10.7B | 10.9B | 175M | 234M |
| Shareholders' Equity | 9.97B | 9.61B | 9.18B | 8.91B | 8.69B | 9.34B | 9.87B | 10.1B | -29.4M | -84.7M |
| Cash & Short-term Investments | 8.00M | 14.0M | 6.00M | 3.00M | 5.00M | 1.00M | 5.00M | 2.00M | 127M | 113M |
| Total Debt | 7.63B | 7.56B | 7.38B | 7.24B | 7.26B | 7.28B | 5.96B | 5.95B | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.77B | 2.71B | 2.80B | 2.59B | 2.65B | 2.44B | 3.79B | 3.33B | -20.4M | -41.6M |
| Capital Expenditure | 1.27B | 1.26B | 1.17B | 1.25B | 1.26B | 1.33B | 1.04B | 1.06B | 3.54M | 2.41M |
| Free Cash Flow | 1.51B | 1.45B | 1.64B | 1.34B | 1.39B | 1.11B | 2.75B | 2.28B | -23.9M | -44.0M |
| Ratios | ||||||||||
| ROE | 8.5% | 10.0% | 10.6% | 12.1% | 12.5% | 17.7% | 16.9% | 18.1% | - | - |
| ROA | 5.1% | 6.0% | 4.3% | 5.0% | 5.1% | 7.9% | 8.1% | 8.7% | -19.2% | -39.1% |
| Net Profit Margin | 9.6% | 11.0% | 11.0% | 12.0% | 12.2% | 19.4% | 19.6% | 22.4% | -1,002.0% | -431.4% |
| Debt to Equity | 0.76x | 0.79x | 0.80x | 0.81x | 0.84x | 0.78x | 0.60x | 0.59x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
City Therapeutics, Inc. Common Stock dividends
City Therapeutics, Inc. Common Stock has not paid dividends in the last 10 fiscal years.
Who owns City Therapeutics, Inc. Common Stock
- Insiders 7.37%
- Institutions 50.82%
- Public & others 41.81%
- Shares outstanding 50.3M
- Free float 2.56M
Top funds holding CTY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Tema Heart & Health ETF | 10.7K | 0.02% | 0.00% | Oct 2026 |
| Tema Healthcare AI ETF | 8.96K | 0.02% | 0.00% | Oct 2026 |
| T. Rowe Price Biotech ETF | 888.00 | 0.00% | +5.84% | Oct 2026 |
City Therapeutics, Inc. Common Stock company profile
- Company name
- City Therapeutics, Inc. Common Stock
- Ticker
- CTY.US
- Exchange
- USA Stocks
- Listed since
- Oct 16, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Fiscal year end
- December
- Address
- 399 Binney Street, Cambridge, MA, United States, 02142
- Phone
- 857 357 2024
- Website
- citytx.com
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts.
City Therapeutics, Inc. Common Stock management
10- Dr. John Michael Maraganore M.D., Ph.D.Co-Founder & Executive Chair · born 1962
- Dr. Andrew C. Orth M.B.A.President, CEO & Director · born 1970
- Dr. Tracy Zimmermann Ph.D.Chief Scientific Officer · born 1970
- Dr. Baisong Mei M.D., Ph.D.Chief Medical Officer · born 1964
- Mr. Sebastian Trousil Ph.D.Co-Founder & COO · born 1984
- Dr. Ari Nowacek M.B.A., M.D., Ph.D.Co-Founder & SVP of Corporate Development
- Dr. Kotaro Nakanishi Ph.D.Co-Founder & Scientific Advisor
- Mr. Mark T. Keating M.D.Co-Founder & Scientific Advisor
- Dr. Yukihide Tomari Ph.D.Co-Founder & Scientific Advisor
- Dr. Phillip D. Zamore Ph.D.Co-Founder & Scientific Advisor